Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity

Overview

This study will compare two bariatric surgical interventions in terms of weight loss, gastroesophageal reflux, and effects on obesity-related comorbid conditions in morbidly obese patients.

Full Title of Study: “Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Randomized Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: December 2026

Detailed Description

Sleeve gastrectomy is an established therapeutic option for morbidly obese patients without preexisting gastroesophageal reflux disease. The novel single anastomosis sleeve ileal bypass (SASI) procedure is already introduced in Norway at a private high-volume bariatric hospital. The purpose of this study is to evaluate the effects of SASI in comparison to an established bariatric procedure, i.e. sleeve gastrectomy. The primary end point is 2-year changes in BMI after sleeve gastrectomy and SASI.

Interventions

  • Procedure: Single anastomosis sleeve ileal bypass
    • The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient’s left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
  • Procedure: Sleeve gastrectomy
    • In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.

Arms, Groups and Cohorts

  • Experimental: Single anastomosis sleeve ileal bypass
    • A Single anastomosis sleeve ileal bypass procedure is performed.
  • Active Comparator: Sleeve gastrectomy
    • A sleeve gastrectomy procedure is performed.

Clinical Trial Outcome Measures

Primary Measures

  • Changes in body-mass index (BMI)
    • Time Frame: 2 year
    • Weight in kilograms divided by the square of the height in meters after sleeve gastrectomy and SASI.

Secondary Measures

  • Change in prevalence of esophagitis.
    • Time Frame: 2 year
    • Changes in the prevalence of esophagitis as evaluated by upper endoscopy.
  • Change in prevalence of gastroesophageal reflux disease.
    • Time Frame: 2 year
    • Changes in the prevalence of gastroesophageal reflux disease as evaluated by 24-hour pH measurements.
  • Complications
    • Time Frame: 6 weeks (100 days for deaths), 2 year, 5 year
    • Complications during surgery, postoperative complications (within 6 weeks [100 days for deaths]) as defined by the Accordion severity grading system and long-term complications.
  • Obesity-related comorbid conditions.
    • Time Frame: 2 year, 5 year
    • Changes in obesity-related comorbid conditions.
  • Vitamin concentrations
    • Time Frame: 2 year, 5 year
    • Changes in vitamin levels (A, B1, B6, B9, B12, C, D, K).
  • Health-related quality of life
    • Time Frame: 2 year, 5 year
    • The RAND 36-Item Short Form Health Survery is a self-reporting questionnaire. Items are scored from 0 (lowest score) to 100 (highest possible score).
  • Obesity-related symptoms
    • Time Frame: 2 year, 5 year
    • Obesity-related Problem scale
  • Gastrointestinal symptoms
    • Time Frame: 2 year, 5 year
    • GSRS
  • Gastroesophageal reflux disease symptoms
    • Time Frame: 2 year, 5 year
    • GERDq
  • Bowel habits
    • Time Frame: 2 year, 5 year
    • Bowel habit questionnaire
  • Revisional surgery
    • Time Frame: 2 year, 5 year
    • Revisional surgery rates in the two groups.
  • Long-term changes in BMI
    • Time Frame: 5 years
    • BMI (weight in kilograms divided by the square of the height in meters) after sleeve gastrectomy and SASI.
  • Body composition
    • Time Frame: 2 years
    • Changes in percentage fat mass and lean mass; percentage change in bone mineral density in lumbar spine (L1-L4), femoral neck, and total hip as assessed by DEXA scan.

Participating in This Clinical Trial

Inclusion Criteria

1. Morbid obesity at referral for bariatric surgery (i.e. a body-mass index [BMI] of ≥35 kg/m2 with obesity-related comorbid conditions or ≥40 kg/m2 with or without such comorbidities). 2. Age 20-60 years. 3. Previous failed attempts of weight loss. 4. Norwegian speaking patients. Exclusion Criteria:

1. BMI ≥55 kg/m2. 2. A history of major abdominal or bariatric surgery (excluding appendectomy, cholecystectomy, and sectio). 3. Established disabling cardiopulmonary disease, ongoing treatment for cancer, long-term steroid use, and conditions believed to be associated with poor adherence after surgery. 4. Previous or current gastroesophageal reflux symptoms with daily use of antireflux medication. Patients are also excluded if preoperative manometry identifies a hiatal hernia (≥4cm in axial length) or if preoperative upper endoscopy identifies esophagitis grade C or D (LA classification), peptic stricture, Barrett's esophagus, or esophageal carcinoma. 5. Achalasia 6. Pregnancy.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Oslo University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Torgeir Søvik, Principal Investigator – Oslo University Hospital
  • Overall Official(s)
    • Torgeir T Søvik, MD, PhD, Principal Investigator, Oslo University Hospital
  • Overall Contact(s)
    • Helene M Haug, MD, +47 22 11 80 80, b31831@ous-hf.no

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.